References

1. 1.
   ZENG H L，QIU Q，FU T X，et al.Development and optimization of sustained release triptolide microspheres［J］.PLoS One，2023，18（10）：e0292861.
2. 2.
   WANG T，SUN K，LI J Y，et al.Study of triptolide on liver injury and detoxification strategy［J］.Chin J Exp Tradit Med Form，2024，30（6）：196-204.
3. 3.
   LIU X，QIU M L，HU X F，et al.Advance in anti-organ fibrosis mechanism of triptolide［J］.Chin Tradit Herb Drugs，2024，55（10）：3569-3578.
4. 4.
   LIU M M，CHEN H，QIAN J C，et al.Construction of triptolide prodrug liposome nanosystem and evaluation of its anti-pancreatic cancer activity［J］.Chin Pharm J，2024，59（10）：911-920.
5. 5.
   CAO Z W.The compatibility detoxification mechanism of glycyrrhizic acid regulating mitochondrial homeostasis of hepatocytes to improve the hepatotoxicity of triptolide［D］.Beijing：China Academy of Chinese Medical Sciences，2024.
6. 6.
   YU L，WANG Z，MO Z，et al.Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy［J］.Acta Pharm Sin B，2021，11（7）：2004-2015.
7. 7.
   ZHAO X，YANG Y，SU X，et al.Transferrin-modified triptolide liposome targeting enhances anti-hepatocellular carcinoma effects［J］.Biomedicines，2023，11（10）：2869.
8. 8.
   CHEN X M，LIN Z Z，CHEN J M，et al.Research progress of nano-formulation of triptolide and its derivatives［J］.Pharm Care Res，2021，21（6）：401-403，411.
9. 9.
   HUANG W，LIU C，XIE L，et al.Integrated network pharmacology and targeted metabolomics to reveal the mechanism of nephrotoxicity of triptolide［J］.Toxicol Res（Camb），2019，8（6）：850-861.
10. 10.
    YAN L.Triptolide-induced nephrotoxicity from the perspective of DNA methylation［D］.Beijing：China Academy of Chinese Medical Sciences，2024.
11. 11.
    CUI J K，ZHU Z L，LIU M J，et al.Study on the molecular mechanism of triptolide in the treatment ofrheumatoid arthritis based on transcriptome sequencing，network pharmacology，and toxicology［J］.Nat Prod Res Dev，2025，37（5）：957-964.
12. 12.
    LI Y Q，WANG H，LI M Q，et al.Research progress in reproductive toxicity of triptolide and ways of mitigation［J］.Chin J Pharmacol Toxicol，2022，36（2）：155-160.
13. 13.
    FAN Y，FSU X H，XU Y，et al.Effect of triptolide on reproductive toxicity in female rats with Ⅱ type collagen induced arthritis［J］.China J Chin Mater Med，2024，49（11）：3061-3069.
14. 14.
    LI X R，YANG D H，HUANG F J，et al.Research progress on germ cell apoptosis induced by triptolide［J］.Guangxi J Tradit Chin Med，2022，45（1）：77-79.
15. 15.
    JIANG S，WAN F，LIAN H，et al.Friend or foe？The dual role of triptolide in the liver，kidney，and heart［J］.Biomed Pharmacother，2023，161：114470.
16. 16.
    QI X M，QIAO Y B，ZHANG Y L，et al.PGC-1α/NRF1-dependent cardiac mitochondrial biogenesis：A druggable pathway of calycosin against triptolide cardiotoxicity［J］.Food Chem Toxicol，2023，171：113513.
17. 17.
    DING Y Y，LI J M，GUO F J，et al.Triptolide upregulates myocardial forkhead helix transcription factor P3 expression and attenuates cardiac hypertrophy［J］.Front Pharmacol，2016，7：471.
18. 18.
    CHENG Y，ZHAO Y，ZHENG Y.Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity［J］.Chin Med，2021，16（1）：114.
19. 19.
    XU T，ZHU Y，GE S，et al.The roles of TPL in hematological malignancies［J］.Hematology，2023，28（1）：2231765.
20. 20.
    HAN J J，LIU F，ZHANG X L，et al.Research progress on structural modification and pharmacological activity of main active components of Tripterygium wilfordii［J］.J China Pharm，2016，27（4）：560-562.
21. 21.
    MA L L，LV L L，DU Y M，et al.Impacts of triptolide on tumor growth，immune microenvironment and TLR4/NF-κB signaling pathway in MGC-803 gastric cancer bearing mice［J］.J Hubei Univ Tradit Chin Med，2024，26（4）：9-13
22. 22.
    ZHANG H R，LI Y P，SHI Z J，et al.Triptolide induces PANoptosis in macrophages and causes organ injury in mice［J］.Apoptosis，2023，28（11/12）：1646-1665.
23. 23.
    ZHANG Z Q，WU J，QING Y L，et al.Triptolide attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting ferroptosis［J］.Chin J Pathophysiol，2024，40（4）：662-669.
24. 24.
    SONG Q N，LI M，LI G X，et al.The mechanism of triptolide in improving lung function and endoplasmic reticulum stress in bleomycin-induced pulmonary fibrosis model mice［J］.Lishizhen Med Mater Med Res，2022，33（12）：2971-2973.
25. 25.
    LI Z F，LI C H，ZHOU B W，et al.Effects of Tripterygium wilfordii polyglycosides on a rat model of pulmonary fibrosis via miR-146/NF-κB signaling pathway［J］.Chin Tradit Pat Med，2024，46（10）：3242-3248.
26. 26.
    CHEN C，YANG S，ZHANG M，et al.Triptolide mitigates radiation-induced pulmonary fibrosis via inhibition of axis of alveolar macrophages-NOXes-ROS-myofibroblasts［J］.Cancer Biol Ther，2016，17（4）：381-389.
27. 27.
    FANG Z，SHEN G，LOU C，et al.Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury［J］.IBRO Neurosci Rep，2024，17：13-21.
28. 28.
    ZENG L S，YANG P，QIN Y Y，et al.Pharmacological activity and clinical progress of Triptolide and its derivatives LLDT-8，PG490-88Na，and Minnelide：A narrative review［J］.Eur Rev Med Pharmacol Sci，2023，27（21）：10181-10203.
29. 29.
    SUN M S.Metabolism-based structure modification and biological activityStudy of triptolide［D］.Dalian：Dalian University of Technology，2018.
30. 30.
    ZHOU Y Q，PENG L，ZHANG Y C，et al.Research progress on structure optimization and biological activity of triptolide［J］.Chin Pharm J，2024，59（19）：1795-1806.
31. 31.
    CHEN X，GUAN J，LIN Y，et al.Design and synthesis of novel sulfur-substituted triptolide with the ability to induce autophagy through inhibition of SRSF1 expression［J］.Eur J Med Chem，2025，287：117342.
32. 32.
    ZHU H，WANG Z，CUI J，et al.PEGylated retinoate prodrug self-assembled nanomicelles loaded with triptolide for targeting treatment of rheumatoid arthritis and side effect attenuation［J］.Colloids Surf B Biointerfaces，2025，251：114618.
33. 33.
    PATEL J，SADIQ H，CATANZARO J，et al.SUPPORT-AF Ⅳ：Supporting use of AC through provider prompting about oral anticoagulation therapy for AF clinical trial study protocol［J］.Cardiovasc Digit Health J，2021，2（4）：222-230.
34. 34.
    ZHU W J，LI N，WANG M，et al.Biopharmaceutical classification system of triptolide［J］.Lishizhen Med Mater Med Res，2023，34（7）：1586-1589.
35. 35.
    ODAGI M，MATOBA T，NAGASAWA K.Enantioselective total synthesis of cepharatines via bioinspired ring reconstruction［J］.J Org Chem，2022，87（2）：1065-1073.
36. 36.
    MEI Z，LI X，WU Q，et al.The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle［J］.Pharmacol Res，2005，51（4）：345-351.
37. 37.
    CHENG C L.Design synthesi and biologicalacyivity study of triptolidederivayives［D］.Beijing：Beijing University of Chemical Technology，2022.
38. 38.
    QI X M，ZHANG W Z，ZUO Y Q，et al.Nrf2/Nrf1 signaling activation and crosstalk amplify mitochondrial biogenesis in the treatment of triptolide-induced cardiotoxicity using calycosin［J］.Cell Biol Toxicol，2024，41（1）：2.
39. 39.
    LI M，LI J，TANG Q，et al.Potential antitumor activity of triptolide and its derivatives： Focused on gynecological and breast cancers［J］.Biomed Pharmacother，2024，180：117581.
40. 40.
    XU B，WANG Z，ZHANG H，et al.The cytoprotective effect of C60 derivatives in the self-microemulsifying drug delivery system against triptolide-induced cytotoxicity in vitro［J］.Molecules，2024，29（17）：4073.
41. 41.
    SU J，CHEN X，YE F，et al.Celastrol derivative/DOX co-assembled nanodrug for enhanced antitumor therapy［J］.Curr Drug Deliv，2024.
42. 42.
    XING W L.Mitochondria-targeted triptolide derivatives synthesis and their antitumor activities［D］.Jinan：Shandong University，2022．
43. 43.
    WANG Q，LIU N，DENG Y，et al.Triepoxide formation by a flavin-dependent monooxygenase in monensin biosynthesis［J］.Nat Commun，2023，14（1）：6273.
44. 44.
    ZHANG S，LIU L，YUE B，et al.Seven lower toxicity celastrol derivatives by biotransformation of Pestalotiopsis sp. LGT-1［J］.Phytochemistry，2023，213：113750.
45. 45.
    XU C，SONG R J，LU P，et al.pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy［J］.Int J Nanomedicine，2018，13：7229-7249.
46. 46.
    TIAN N，ZHANG Y Q，LI W，et al.Transporter-mediated nano-delivery system in promoting oral absorption of drugs：A review［J］.Chin J Exp Tradit Med Form，2024，30（2）：254-266.
47. 47.
    XU L，QIU Y，XU H，et al.Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents［J］.Food Chem Toxicol，2013，57：371-379.
48. 48.
    ZHANG M，YING N，CHEN J，et al.Engineering a pH-responsive polymeric micelle co-loaded with paclitaxel and triptolide for breast cancer therapy［J］.Cell Prolif，2024，57（6）：e13603.
49. 49.
    ZHU H，WANG Z，CUI J，et al.PEGylated retinoate prodrug self-assembled nanomicelles loaded with triptolide for targeting treatment of rheumatoid arthritis and side effect attenuation［J］.Colloids Surf B Biointerfaces，2025，251：114618.
50. 50.
    GUO R B，ZHANG X Y，YAN D K，et al.Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy［J］.Biomater Sci，2022，10（2）：499-513.
51. 51.
    ZHAO X，YANG Y，SU X，et al.Transferrin-modified triptolide liposome targeting enhances anti-hepatocellular carcinoma effects［J］.Biomedicines，2023，11（10）：2869.
52. 52.
    RONCA R，SUPURAN C T.Carbonic anhydrase Ⅸ：An atypical target for innovative therapies in cancer［J］.Biochim Biophys Acta Rev Cancer，2024，1879（4）：189120.
53. 53.
    FENG K，LI X，BAI Y，et al.Mechanisms of cancer cell death induction by triptolide：A comprehensive overview［J］.Heliyon，2024，10（2）：e24335.
54. 54.
    CHEN H，WANG X，LIU M，et al.Synergism and attenuation of triptolide through prodrug engineering combined with liposomal scaffold strategy to enhance inhibition in pancreatic cancer［J］.Int J Pharm，2023，648：123623.
55. 55.
    PAN R，TANG J Z，ZHANG H L，et al.Effect of folic acid-modified crebanine polyethylene glycol-polylactic acid hydroxyacetic acid copolymer nanoparticles combined with ultrasonic irradiation on subcutaneous tumor growth of liver cancer in mice［J］.Chin J Exp Tradit Med Form，2025，31（4）：217-225.
56. 56.
    ZHANG L，CHANG J，ZHAO Y，et al.Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis［J］.Int J Nanomedicine，2018，13：2051-2064.
57. 57.
    BA L，E M，WANG R，et al.Triptolide attenuates cardiac remodeling by inhibiting pyroptosis and EndMT via modulating USP14/Keap1/Nrf2 pathway［J］.Heliyon，2024，10（2）：e24010.
58. 58.
    LI Z，YANG G，HAN L，et al.Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma［J］.J Nanobiotechnology，2021，19（1）：360.
59. 59.
    LUO Y，LI J，HU Y，et al.Injectable thermo-responsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on "two strikes" effects［J］.Acta Pharm Sin B，2020，10（11）：2227-2245.
60. 60.
    ZHAO X，LIU X，ZHANG P，et al.Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma［J］.Acta Pharm Sin B，2019，9（5）：1050-1060.
61. 61.
    GUO B，QIAO F，LIAO Y，et al.Triptolide laden reduced graphene oxide transdermal hydrogel to manage knee arthritis：In vitro and in vivo studies［J］.J Biomater Sci Polym Ed，2021，32（10）：1288-1300.
62. 62.
    HAN K，XIE F，ANIMASAHUN O，et al.Inulin-gel-based oral immunotherapy remodels the small intestinal microbiome and suppresses food allergy［J］.Nat Mater，2024，23（10）：1444-1455.
63. 63.
    GU Y，DU Y，JIANG L，et al.αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma［J］.J Nanobiotechnology，2022，20（1）：384.
64. 64.
    ZENG H L，QIU Q，FU T X，et al.Development and optimization of sustained release triptolide microspheres［J］.PLoS One，2023，18（10）：e0292861.
65. 65.
    ZHANG J.Preparation and pharmacodynamic evaluation of triptolide self-microemulsifying drug delivery system［D］.Hangzhou：Zhejiang University，2019.
66. 66.
    SHAO Y Y，ZAHNG C N，WANG J，et al.Current status and development considerations of detoxification research on toxic traditional Chinese medicine compatibility［J］.Chin Tradit Herb Drugs，2025，56（4）：1394-1403.
67. 67.
    ZHOU W J，CHAI Z，LI Y Y，et al.Protective effects of Guipi decoction on hepatocyte mitochondria in liver injury rat induced by extract from Tripterygium wilfordii by ethanol［J］.J Shanxi Coll Tradit Chin Med，2018，19（4）：24-26，29.
68. 68.
    YANG J X，XU H ，HAN G Z，et al.Studies on counteractive effects of Wuzi Siwu Guashitang against GTW-induced genital system toxicity in male rats and its mechanism［J］.Chin Tradit Herb Drugs，2002（7）：59-61.
69. 69.
    SU X L.Clinical observation of Banxia Xiexin Tang in children with purpuric nephritis（isolated hematuria） of cold and heat mixed pattern［D］.Chengdu：Chengdu University of Traditional Chinese Medicine，2021.
70. 70.
    CHEN W J，WU J J.Research progress on the toxicity of Tripterygium wilfordii and detoxification by traditional chinese medicine compatibility［J］.Chin Tradit Pat Med，2023，45（2）：499-503.
71. 71.
    CHAI Z，FAN H J，WANG Y H，et al.Effect of sini powder on acute liver injury induced by tripterygium glycosides［J］.World J Integr Tradit West Med，2012，7（2）：120-123.
72. 72.
    SONG X D，GAO C.Progress on pharmacology，toxicity and attenuated strategies of Tripterygium wilfordii［J］.J Gannan Med Univ，2023，43（10）：987-992，1004.
73. 73.
    XIE T，LI H，LU Y，et al.Effects of Qingluo Tongbi decoction combined with radix rehmanniae recens and Radix Notoginseng on hepatotoxicity of Tripterygium wilfordii based on metabonomics［J］.China J Tradit Chin Med Pharm，2017，32（8）：3462-3467.
74. 74.
    ZHANG W Z，QI X M，ZUO Y Q，et al.Protective effect and mechanism of astragalus membranaceus and angelica sinensis compatibility against triptolide-induced hepatotoxicity by regulating Keap1/Nrf2/PGC-1α［J］.China J Chin Mater Med，2023，48（23）：6378-6386.
75. 75.
    LI F Z，WAN L，ZHAO L，et al.To explore the mechanism of tripterygium wilfordii-white peony in rheumatoid arthritis based on network pharmacology and animal experiments［J］.China Mod Doc，2023，61（36）：95-100，111.
76. 76.
    SUN L H，DING Y，HAN S S，et al.Analysis of regularity of traditional Chinese medicine for attenuating female reproductive toxicity of Tripterygium wilfordii based on literature mining［J］.Chin Tradit Herb Durgs，2023，54（6）：1886-1895.
77. 77.
    CAO Z P，WANG Y P.The mechanism of Huangqi-Leigongteng couplet medicines in the treatment ofprimary membranous nephropathy based on network pharmacology andmolecular docking technology［J］.Clin J Chin Med，2024，16（30）：23-34.
78. 78.
    WU X，WU D L，WEI L B，et al.Mechanism of Astragali Radix in reducing the nephrotoxicity of Tripterygium Wilfordii based on network toxicology combined with network pharmacology and experimental verification［J］.Pharmacol Clin Chin Mater Med，2024，40（9）：83-88.
79. 79.
    YAN Y Y，YAN M，WU X X，et al.Study on protective effects of crocin against triptolide-induced visceral organ injury in mice［J］.China Pharm，2021，32（19）：2320-2326.
80. 80.
    DU X H.Experi mental study on reducing toxicity and synergism of Tripterygium wilfordii combined with Leonurus artemisia in treating rheumatoid arthritis［D］.Hangzhou：Zhejiang Chinese Medical University，2020.
81. 81.
    SONG L L，WANG J M，GONG M Z，et al.Mechanism of Rehanniae Radix drug decoction on reducing the hepatotoxicity induced by Tripterygium wilfordii Hook.f［J］.China J Tradit Chin Med Pharm，2023，38（5）：2251-2256.
82. 82.
    LI H.The Compatibility for attenuation and metabolomics mechanism study of Tripterygium compound based on "different types of mutual restraint" hypothesis［D］.Nanjing：Nanjing University of Chinese Medicine，2015.
83. 83.
    WANG Y M，WANG J M，GUAN Y C，et al.Optimization of processing and detoxification process for leigongteng（Tripterygium wilfordii）boiled in Jinqiancao（Lysimachia christinae）decoction and preliminary exploration of related mechanism［J］.Chin Arch Tradit Chin Med，2023，42（3）：253-258.
84. 84.
    SONG L L，WANG J M，GONG M Z，et al.Experimental study of Jinqiancao（Lysimachia christinae）reducing nephrotoxicity induced by Leigongteng（Tripterygium wilfordii） in mice［J］.Chin Arch Tradit Chin Med，2023，41（4）：50-54.
85. 85.
    WU X H，WANG J M，LI B Y，et al.Detoxification mechanism of "Lysimachiae Herba suppressing Tripterygium wilfordii toxicity" based on component combination and testicular toxicity［J］.China J Tradit Chin Med Pharm，2022，37（5）：2781-2787.
86. 86.
    DENG Y.A comparative study on the pharmacokinetics of dihydromyricetin and its derivatives in Ampelopsis grossedentata and the detoxification study of their combination with triptolide［D］.Changsha：Hunan University of Chinese Medicine，2017.
87. 87.
    WEI C B，ZHOU L D，ZHANG J W，et al.Rotective effects of quercetin against the triptolide induced liver injury and relevant mechanism study［J］.J Sichuan Univ（Med Sci Ed），2019，50（5）：684-688.
88. 88.
    WANG L.Preventive effect of silymarin and selenium-enriched cordyceps militaris on triptolide-induced acute hepatotoxicity in rats［D］.Guangzhou：Guangzhou University of Chinese Medicine，2017.
89. 89.
    ZHOU Y Y，LU X Y，XIA L，et al.Arctiin antagonizes triptolide-induced renal toxicity in rats via anti-inflammatory pathway［J］.Acad J First Med Coll PLA，2020，40（10）：1399-1405.
90. 90.
    QI Z X.Integrated analysis of transcriptome and metabolome of Lonicera maackii fruit in different developmental stages unveil the biosynthesis pathway of chlorogenic acid and dynamic accumulation pattern of flavonoids［D］.Beijing：Beijing Forestry University，2022.
91. 91.
    GUAN Y M，WAN Z Y，WANG S H，et al.Combination of components from tripterygii radix et rhizoma-chuanxiong rhizoma affects RA-FLSs by regulating NF-κB，Nrf2/HO-1 signaling pathways and Bcl-2/Caspase-3 expression［J］.Chin J Exp Tradit Med Form，2025，31（2）：17-26.
92. 92.
    CHEN C C.Evaluation of the effect of tripterygium polyglycosides combined with piperazine ferulate in the treatment of patients with chronic glomerulonephritis［J］.J Qiqihaer Med Coll，2022，43（17）：1626-1629.
93. 93.
    ZHOU Y Y，SUN Y，LI P，et al.Monoside antagonizes triptolide-induced hepatocyte apoptosis via the anti-oxidative stress pathway［J］.Acad J First Med Coll PLA，2018，38（8）：949-955.
94. 94.
    PENG X，LI Q，TIAN L L，et al.Effects of triptolide combined with doxorubicin on the apoptosis of hepatocellular carcinoma Huh7 Cells［J］.Pharmacol Clin Chin Mater Med，2023，39（8）：52-57.
95. 95.
    CHEN N，PENG T Y，ZHANG W M，et al.Synergistic pro-apoptotic effect of triptolide combined with doxorubicin in human breast cancer cell line MCF-7［J］.Basic Med Sci Clin，2023，43（8）：1186-1192.
96. 96.
    ZHANG Y，GUO F.Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells［J］.J China Pharm，2023，34（18）：2219-2225.
97. 97.
    YANG X H.Triptolide enhances liver injury by inhibiting its metabolic enzyme cytochrome P450 3A4［D］.Hefei：Anhui Medical University，2020.
98. 98.
    LI Y M.Melatonin regulates PI3K/Akt/mTOR autophagy pathway in the treatment of premature ovarian insufficiency［D］.Jinan：Shandong University，2020.
99. 99.
    SUN H，LI C P.Clinical observation on tripterygium glycosides and metformin in treating diabetic nephropathy［J］.West J Tradit Chin Med，2014，27（7）：82-84.
100. 100.
     FAN H J，WANG L，LI Y Y.Application of tripterygium glycoside tablets combined with valsartan in diabetic nephropathy patients［J］.World J Comp Med，2023，9（8）：145-147，155.
101. 101.
     JIN J.Observation on the clinical effect of Tripterygium wilfordii polyglycosides combined with iguratimod in the treatment of rheumatoid arthritis［J］.Chin J Mod Appl Pharm，2022，16（6）：165-167.
102. 102.
     TANG L H.The detoxification effect of vitamin K family on the triptolide from Tripterygium wilfordii as an anticoagulant rodenticide［J］.Chin J Hygien Insect Equip，2018，24（4）：333-335.
103. 103.
     YU C.TLR signaling pathway of dendritic cells in inflammatory bowel disease（Crohn's disease）and efects of triptolide on it［D］.Nanjing：Nanjing University，2011.